Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03568448 · ClinicalTrials.gov registry record
Monitoring Response to Neoadjuvant Chemotherapy in HER2 Negative Breast Cancer Using High-speed MR Spectroscopic Imaging
A clinical trial of HER2-Negative Breast Cancer, sponsored by New Mexico Cancer Research Alliance.
- Active
- Registry status
- 30
- Enrollment target
- 1
- Study location
NCT03568448 is a study of HER2-Negative Breast Cancer that is active but no longer recruiting, run by New Mexico Cancer Research Alliance. The registered enrollment target is 30 participants, below the 254-participant average among 49 other HER2-Negative Breast Cancer trials with a reported enrollment target (88% lower). The trial reports 1 study location across 1 state.
The verdict
NCT03568448, a study of HER2-Negative Breast Cancer, is active but no longer recruiting, sponsored by New Mexico Cancer Research Alliance.
- ACTIVE NOT RECRUITING
- Registry status
- 30 participants
- Enrollment target
- 1
- Study location
Study Summary
The study will assess whether changes in total choline concentration \[tCho\] during neoadjuvant chemotherapy (NAC) are predictive of pathologic complete response (pCR) in patients with HER2 negative breast cancer (HNBC) appropriate for NAC, and compare these findings with dynamic contrast enhanced magnetic resonance imaging (DCE-MRI). The objective is to assess the predictive value of changes in the concentration and spatial extent of tCho within the tumor during NAC.
Conditions Studied
Interventions
- OTHER Response monitoring (no intervention)
Study Locations (1)
New Mexico
- University of New Mexico Comprehensive Cancer Center - Albuquerque
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2018-04-16 |
| Est. Completion | 2027-12-31 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03568448
The ClinicalTrials.gov registry entry for NCT03568448 describes a study currently listed as active not recruiting, categorized as an unspecified phase. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 254-participant average among 49 other HER2-Negative Breast Cancer trials with a reported enrollment target (88% lower). The listed sponsor is New Mexico Cancer Research Alliance, which has 66 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with HER2-Negative Breast Cancer appearing as the primary indexed condition, and to 1 intervention - of which Response monitoring (no intervention) is the first listed.
NCT03568448 reports 1 study location spanning 1 distinct geographic area - top geographies include New Mexico.
Frequently Asked Questions
What is clinical trial NCT03568448 about?
NCT03568448 is a clinical study titled "Monitoring Response to Neoadjuvant Chemotherapy in HER2 Negative Breast Cancer Using High-speed MR Spectroscopic Imaging". The study will assess whether changes in total choline concentration \[tCho\] during neoadjuvant chemotherapy (NAC) are predictive of pathologic complete response (pCR) in patients with HER2 negative breast cancer (HNBC) appropriate for NAC, and compare these findings with dynamic contrast enhanced ...
What is the current status of trial NCT03568448?
This trial is currently active not recruiting. The enrollment target is 30 participants. The study started on 2018-04-16. Estimated completion is 2027-12-31.
What conditions does trial NCT03568448 study?
This clinical trial studies the following conditions: HER2-Negative Breast Cancer.
What interventions are being tested in trial NCT03568448?
The interventions under investigation include: Response monitoring (no intervention) (OTHER).
Who is sponsoring clinical trial NCT03568448?
This trial is sponsored by New Mexico Cancer Research Alliance, which has 66 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03568448 being conducted?
This trial has 1 study location across New Mexico. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for HER2-Negative Breast Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Tirzepatide for Weight Loss Intervention in Early-Stage Hormone Receptor Positive/HER2 Negative Breast Cancer
RECRUITING · Phase 2
-
Impact of Omitting Chemo Based on Patient's Selection for ER-Positive, HER2-Negative Breast Cancer With Ribociclib and Endocrine Therapy
RECRUITING · Phase 2
-
A Study to Evaluate the Safety and Therapeutic Activity of GI-102 As a Single Agent and in Combination with Conventional Anti-cancer Drugs, Pembrolizumab or Trastuzumab Deruxtecan(T-DXd) in Patients with Advanced Solid Tumors (KEYNOTE-G08)
RECRUITING · Phase 1
-
A Phase 2 Study of PCS6422 With Capecitabine in Patients With Advanced or Metastatic Breast Cancer
RECRUITING · Phase 2
-
I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer
RECRUITING · Phase 2
-
PRE-I-SPY Phase I/Ib Oncology Platform Program
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.